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Abstract 
 
At present, the main form of insulin administration is the invasive subcutaneous route, and this for 
many individuals means managing their glucose levels with multiple daily injections, which is both 
painful and difficult to administer chronically. To increase patient compliance, products are slowly 
reaching the market that are more patient friendly such as the insulin patch-pump systems, like 
Omnipod and V-Go, but also the inhaled insulin Afrezza® and the buccal insulin Oral-lyn™. This review 
outlines the history of insulin, the various options that are currently available in practice for insulin 
delivery, and the non-invasive delivery systems that have managed to enter the different stages of 
clinical trials in the past decade. 
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1 Introduction 
 
Diabetes Mellitus is a metabolic disease characterised by deficiency or development of resistance to 
insulin or in some cases both. In 2012, around 1.5 million deaths were caused by the disease and 
according to the 2016 WHO Global report on diabetes the estimated number of adults with the 
condition increased considerably from 108 million in 1980 to 422 million in 2014 [1]. It was predicted 
by Wild et al. that a total of 366 million people would be with diabetes in 2030, but based on the 
International Diabetes Federation (IDF) this prediction was already reached in 2011, and it was 
estimated by 2030 the number would be much greater with as many as 552 million adults [2,3]. In the 
latest estimation, published in 2018 and shown in Table 1, the IDF estimated the number of adults 
(aged 18-99 years) with diabetes to be 451 million, in 2017, and the projection for 2045 is a substantial 
increase to 693 million [4].  
 
Table 1. Estimated number and prevalence of adults with diabetes [4].  
Year Number (millions) Prevalence of adults (%) 
2017 451 8.4% 
2045 693 9.9% 
 
Currently, for insulin-dependent diabetic patients, the main route of insulin administration is the 
parenteral route of administration. For individuals to maintain the correct level of blood glucose in 
many cases this requires them to chronically administer multiple daily injections of either long-acting, 
intermediate-acting, short-acting and/or rapid acting insulin via the subcutaneous route. To increase 
patient compliance, and to reduce the burden of daily painful administration of insulin, many 
researchers are working on the development of novel carrier systems for the safe and effective 
delivery of insulin via non-invasive routes, which mainly include; buccal, oral, pulmonary, nasal and 
transdermal systems. This review summarizes the options that are currently in practice for insulin 
delivery, including Oral-lyn™ and Afrezza®, but the key component of the review covers non-invasive 
delivery formulations that have managed to enter the various stages of clinical trials in the past decade 
[5,6]. The information is primarily based on the database, ClinicalTrials.gov, which is a database of 
clinical studies taking place worldwide and conducted with human participants [7]. 
1.1 Diabetes mellitus 
 
The WHO classifies diabetes mellitus into: type 1, type 2, gestational diabetes and intermediate 
conditions such as impaired glucose tolerance and impaired fasting glycaemia, which can progress into 
diabetes [1]. The two main types of diabetes mellitus are type 1 diabetes (T1DM) and type 2 diabetes 
(T2DM). The aetiology of both T1DM and T2DM is complex and based on current evidence involves 
both genetic and environmental factors [8]. T1DM, also known as early onset, insulin-dependent or 
juvenile diabetes, is caused by absolute deficiency of insulin as a result of autoimmune destruction of 
the insulin producing beta-cells in the pancreas. Around one tenth or less of all diabetics are classified 
as type 1 diabetics and are diagnosed commonly in early childhood or as young adults. T2DM is the 
most common form of diabetes, also known as late onset or non-insulin-dependent diabetes, which 
is responsible for almost all the other cases of diabetes and is caused because of insulin resistance and 
relative insulin deficiency.  
 
In epidemiological studies, fasting blood plasma glucose of ≥ 7 mmol/L or ≥ 126 mg/dL is accepted for 
diagnosis of diabetes as per the 1999 WHO criteria [9]. Uncontrolled diabetes in the short-term can 
result in dangerous complications such as hypoglycaemia (less than 4 mmol/L), hyperosmolar 
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hyperglycaemic state (often over 40 mmol/L) and diabetic ketoacidosis. In the long-term, diabetic 
patients, often experience other medical problems including cardiovascular disease, kidney failure, 
loss of vision and neuropathy leading to possible leg amputations [1]. The Diabetes Control and 
Complications Trial (DCCT) was able to demonstrate that intensive insulin therapy can delay 
microvascular complications, such as retinopathy and nephropathy in type 1 diabetic patient, and the 
benefits remain for at least four years thereafter [10–12]. On the other hand, in clinical practice, one 
of the drawbacks of controlling blood glucose levels too strictly is the increased risk of hypoglycaemic 
episodes.  
1.2 History of insulin 
 
In 1923, two years after the discovery of insulin by Banting and Best, the company Eli Lilly, in 
partnership with the university of Toronto, managed to produce large-scale purified animal insulin, 
which resulted in record profits for the company [13,14]. During the first 60 years of the discovery of 
insulin, optimisation efforts focused on isolation of insulin from animal sources, primarily from bovine 
and porcine pancreata. But later in 1982, after regulatory approval of the world’s first recombinant 
DNA drug, Humulin (human insulin), by the United Kingdom, United States, West Germany and the 
Netherlands, the focus on purification processes shifted towards mainly enhancing properties of 
insulin through changes in both the formulation and amino acid composition [15]. In 1996, Eli Lilly and 
company also developed the first commercial insulin analogue, insulin lispro (Humalog), by altering 
the naturally occurring amino acids in positions 28 and 29 of the B-chain to form Lys (B28) and Pro 
(B29) human insulin [15,16]. 
 
In the 21st century, a variety of insulin types are now in clinical practice and the amino acid sequence 
of the insulin differs depending on whether the insulin is human insulin, bovine insulin, porcine insulin 
or analogues of human insulin. Although now bovine insulin is rarely used since the main method of 
production is with recombinant DNA technology using bacteria and yeast [17]. After FDA approval of 
Pfizer’s inhaled insulin product Exubera in 2006, even though the invention was unsuccessful, the main 
efforts now appear to be on producing alternative non-invasive formulations of insulin or analogues 
with transformed properties [18]. The two recent successful developments in the area, both 
developed by Novo Nordisk Limited, include approval of the longer-acting insulin degludec (Tresiba) 
injections by the FDA and European Medicines Agency (EMA) and the most recent ultra-fast rapid-
acting insulin aspart injections known as Fiasp approved by the EMA [19–21]. Fiasp is both faster and 
more stable compared to the conventional insulin aspart (Novorapid® or NovoLog®) due to the 
addition of two extra excipients, nicotinamide and arginine, and hence it is suggested to result in 
insulin release more reflective of physiological insulin [22]. 
1.3 Structure, biosynthesis and properties of insulin 
 
The monomeric human insulin, with a molecular weight of 5.8 kDa, comprises 51 amino acids, which 
is in the form of an A chain of 21 amino acids and a B chain of 30 amino acids. As shown in Figure 1, 
two disulphide bonds connect the A and B chains (A7-B7 & A20-B19) and one disulphide linkage is 
present within the A chain (A6-A11) [23,24]. Insulin in its primary form exists as a chain of 110 amino 
acids, known as preproinsulin, which is translated from insulin mRNA in the cytosol of pancreatic β 
cells [23,25]. There are several factors that control the biosynthesis of insulin, glucose metabolism 
being the central event, which results in the stimulation of insulin gene transcription and mRNA 
translation [26]. 
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During biosynthesis of insulin, the interaction of the signal peptide of preproinsulin with the cytosolic 
ribonucleoprotein signal recognition particle (SRP) facilitates the translocation of the molecule across 
the endoplasmic reticulum (ER) membrane to the luminal side of the rough ER [23,27,28]. In this 
process, the 24 amino acids signal peptide is cleaved off by signal peptidases, which results in the 
formation of the 86 amino acid long proinsulin consisting of the B chain, C peptide and A chain 
[17,29,30]. Within the ER, proinsulin obtains the disulphide linkages, and the required three-
dimensional structure for its function. 
 
Proinsulin transportation from the ER to the Golgi apparatus occur via secretory vesicles and both 
guanosine-5-triphosphate (GTP) and calcium are required for the process [8,31]. As comprehensively 
reviewed by Dunn et al. 2005 in the storage/secretory vesicles of the Golgi apparatus proinsulin starts 
forming zinc and calcium containing dimers and then hexamers. Hence the vesicles serve as storage 
sites for insulin and the C-peptide. In the secretory vesicles, enzymes remove the C-peptides of 
proinsulin to produce mature insulin hexamers, which leads to crystallization of the hexamers due to 
mature insulin being less soluble compared to proinsulin [8,23,32]. Insulin secretion from the 
pancreatic β-cells occurs when the plasma membrane of the storage vesicles fuses with the cell 
membrane in response to high plasma glucose levels. The release of the crystallised insulin hexamers 
from the vesicles in the intercellular space results in the crystals dissolving and releasing the 
biologically active insulin monomers [32]. 
2 Routes of insulin delivery 
 
The aim of insulin therapy, in insulin dependent diabetics, would be to achieve plasma insulin levels 
that mimic as closely as possible the normal secretion of insulin in non-diabetic individuals. This means 
covering both the release of basal or baseline insulin, typically in the range of 5 to 15 microunits per 
millilitre, and insulin released in response to meal intake, which generally results in peak serum insulin 
levels of 60 to 80 microunits per millilitre [17,33]. Since the original discovery of the hormone, the 
main method of insulin administration has been via subcutaneous (sc) injections. Figure 2 shows some 
 
Figure 1: Schematic representation of human insulin comprising of 51 amino acids, which is in the 
form of an A chain of 21 amino acids and a B chain of 30 amino acids. Two disulphide bonds 
connect the A and B chains (A7-B7 & A20-B19) and one disulphide linkage is present within the A 
chain (A6-A11) [23,24].  
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of the various routes of insulin delivery that currently exist and some routes of delivery that are under 
investigation in clinical trials and will be discussed in this review. 
2.1 Insulin therapy currently in clinical practice 
 
Modern subcutaneous administration devices are safer, offer more accurate dosing and have less 
complications compared to the original use of vials; where patients had to draw the prescribed doses 
of insulin from the vials using separate syringes. The innovation of the first pen injector, NovoPen® in 
1985, was a success and now the main form of insulin administration is through the use of pen devices, 
although the original pen device had to be refilled using disposable insulin cartridges, the injection 
pens that are now in more common practice are the completely disposable injection pens such as 
FlexPen® by Novo Nordisk A/S and SoloStar® by Sanofi-Aventis [34]. The main advantages of sc insulin 
therapy include the high bioavailability, the relatively controlled onset of action and the flexibility in 
dosing. The disadvantages include the risk of lipodystrophy, painful administration, bruising of 
injection sites, weight gain and alterations in absorption when the injected limb is used for strenuous 
exercise. In terms of time profile, the onset of action of short-acting insulins, i.e. soluble or regular 
insulins, are around 30-60 minutes, maximal effect occurs at 2-4 hours, and it lasts for up to 8 hours. 
Rapid-acting insulins, compared to regular insulin, are faster in onset and have a shorter duration of 
action. The intermediate acting formulations, such as isophane human insulin (Humulin I), and long-
acting preparations, such as insulin glargine (Lantus), have an onset of action of 1-2 hours, peak levels 
are reached around 4–12 hours, and have a duration of action of 16–42 hours [35]. 
 
 
 
Figure 2: Routes of delivering insulin currently in use and routes of insulin delivery under 
investigation. The routes in the oval shapes represent the routes currently in use but also in 
development (pulmonary, subcutaneous and buccal delivery) and the routes in the diamond 
shapes are main routes currently being trialled in humans (oral, transdermal and nasal delivery). 
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2.2 Subcutaneous insulin patch-pump systems 
 
Using a similar concept to the continuous subcutaneous insulin infusion (CSII) systems, companies are 
now developing more discreet and convenient devices, labelled as the patch-pump systems, which do 
not involve attachment of tubes [36]. Omnipod is such a device and is available in places such as the 
USA, UK, Germany and Israel [37]. The system comes in two parts a small Pod, that is the insulin 
reservoir (200 units of insulin) and delivers insulin via a discreet needle, and a handheld Personal 
Diabetes Manager (PDM), which uses wireless communication to deliver basal insulin continuously. 
The Pod can provide up to 72 hours of insulin [37]. 
 
One of the most simplistic of the patch systems is the V-GoTM device designed by Valeritas, Inc. as it 
does not require batteries, programming or a hand-held remote [38]. The daily disposable V-GoTM 
insulin delivery device is designed to deliver a 24-hour cover of both basal and bolus insulin and is 
suitable for patients on multiple daily injections. The V-Go device is loaded by the patient with U-100 
rapid-acting insulin analogue, compatible with both Humalog (insulin lispro) and NovoLog (insulin 
aspart), using the adapter (EZ fill), which is provided with every 30-day supply of the devices. The 
device is small, lightweight (~1 ounce) and waterproof; after loading, the patient can attach the device 
comfortably and discreetly on the skin of their abdomen, arms or thighs via the hypoallergenic 
adhesive strip [39]. To improve patient comfort, floating needleTM technology is used, which allows 
movement of the needle relative to the device. The push of a button allows the floating needle (30-
gauge and 4.6mm) to be inserted into the subcutaneous tissue, which starts the basal infusion of 
insulin for the whole 24-hour period. The basal rates are pre-set and are available as 20, 30 or 40 units 
of insulin per 24-hours and each one also allows for 36 units of bolus insulin daily. The meal-time 
administration of insulin is initiated by the patient by two simple sequential clicks of the bolus ready 
and bolus delivery buttons. The device was launched by Valeritas, Inc. in May 2012 [38]. 
3 Evaluation of insulin delivery via non-invasive routes 
 
Subcutaneous administration of insulin has some advantages; but being an invasive technique 
alternative routes of administration are being investigated. Although there are other non-invasive 
routes, including vaginal, rectal and ocular, Figure 3 shows a summary of the advantages and 
disadvantages of the main routes being investigated and those are the routes that will be discussed 
here in this review.  
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3.1 Pulmonary insulin delivery 
 
Of the inhaled insulin products that have reached clinical trials, only two products, both dry powder 
inhaler (DPI) systems, have secured FDA approval; one being Exubera, which also had the EMA 
approval in Europe, and Afrezza® [18,49,50]. In 2007, the withdrawal of Exubera from the market by 
Pfizer led to a number other companies, such as Novo Nordisk and Eli Lilly, to discontinue the 
development of their inhaled insulin products around the same time [18]. As reviewed by Heinemann 
(2008) Exubera was unsuccessful due to mainly the design of the device not taking into consideration 
the consumers perspectives. Though theoretically envisioned well for the purpose, in practice, the 
device was large and bulky, hence, difficult for patients to carry around and could not be used with 
discretion. Other factors that contributed to the failure of Exubera include; the unimpressive 
 
Figure 3: Summary of advantages and disadvantages of the main five non-invasive delivery routes (buccal, oral, 
nasal, pulmonary and transdermal) for insulin delivery based on information from several reviews [40–48]. 
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launching of the product, the training required to use the device, the high cost of the product, difficult 
dosing equivalence, the requirement for patients to regularly check their lung function and safety 
concerns with chronic use of the product [18]. 
 
However, another inhaled insulin product is currently in clinical trials, referred to in Table 2, it is the 
pocket-sized insulin inhaler device Dance-501, which uses a vibrating mesh micropump technology 
developed by Aerogen [50]. The device, shown in Figure 4, appears to have some potential for 
achieving pulmonary insulin delivery, based on the recent completion of phase 2 clinical trials. The 
advantages of the Dance-501 is that it is small, discrete, portable and battery operated and hence the 
developers have overcome the disadvantages faced with Exubera, produced by Pfizer [50]. 
Additionally, due to the formulation being a liquid 
aerosol system, the incidence of coughs is lower, 
compared to DPI systems, and the price of using 
this device is said to be comparative to current 
subcutaneous pen devices [50]. One of the 
possible drawbacks of the design is that the insulin 
release is breath actuated, which, without good 
initial training, could result in fluctuating 
bioavailability like current problems faced with 
such inhaler devices used for respiratory diseases. 
Another weakness is that prior to administration, 
precise volumes of the formulation from a 
separate container is required to be dispensed 
into the inhaler reservoir, which adds another 
step to the administration process and the manual 
work required for the process could be a problem 
for arthritic and very elderly patients. There are 
limited studies available for bioavailability of the 
formulation for the Dance-501 device but a study 
completed with 24 type 2 diabetic patients with a 
previous device, called Aerodose using Aerogen’s 
electronic aerosol generator technology, showed 
no significant difference in the relative bioavailability and relative biopotency of inhaled insulin to 
subcutaneous administration of insulin among doses used at fixed ratios [51]. It was found to obtain 
overlapping dose-response curves with inhaled and subcutaneously administered insulin. The amount 
of inhaled insulin to be administered was required to be 10 times greater than the subcutaneous dose 
e.g. 160 units of inhaled insulin was roughly equivalent to 16 units administered using subcutaneous 
injections. The positive outcome from the study also was the fact that the inhaled formulation reached 
maximum serum insulin (Tmax) concentration significantly (P<0.001) faster compared to subcutaneous 
insulin administration, which may be explained by the high permeability across the thin alveolar-
capillary barrier. Moreover, in terms of lung function no serious adverse events or clinically relevant 
changes were observed. Overall, this could be one of the promising formulations to look out for in the 
near future. 
3.2 Buccal insulin delivery 
 
Apart from Generex Oral-lyn™, mentioned below, another interesting new buccal formulation is the 
formulation developed by the joint partnership of MonoSol Rx and Midatech Ltd [47]. The two 
companies have combined their specialities, Midatech’s gold nanoparticle (GNP) technology and 
MonoSol’s PharmFilm drug delivery technology, to form a buccal soluble film product called 
MidaForm® Insulin PharmFilm [52,53]. In this formulation, the recombinant human insulin is bound to 
 
Figure 4: Simplified image of the Dance-501 
device along with a separate insulin 
container. This device uses a vibrating mesh 
micropump technology developed by 
Aerogen; figure adapted from [50]. 
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glycan-coated gold nanoparticles through non-covalent binding and embedded in a polymeric 
mucoadhesive film for delivery of insulin via the buccal mucosa. It is claimed by Midatech Pharm that 
the gold nanoparticle technology helps drugs with permeability through membranes, leads to an 
increase in stability. The particles are also inert and biocompatible [54]. Gold metal atoms form the 
core of the GNPs and these are attached via gold sulphur bonds to an organic layer of glycans. During 
the self-formation process insulin, can attach to the gold core, which is 1-2 nanometers in size. In 
Phase I clinical trials, using insulin aspart, the formulation was shown to be both well tolerated and 
safe [47]. Additionally, owing to their small size GNPs are believed to be eliminated via the liver and 
kidneys. Although the technology looks promising, and the company has facilities to scale up the 
production of the formulation, Midatech made an announcement in May 2016 that the results of the 
phase 2a clinical trials (MTD101) demonstrated low bioavailability for the transbuccal film insulin 
compared to subcutaneous insulin and hence the company were evaluating their options [55]. The 
product is not on the pipeline list of products for Midatech or MonoSol Rx, now renamed as Aquestive. 
It is less likely that the development of MidaForm® Insulin PharmFilm will be advanced.   
3.3 Oral insulin delivery 
 
Novo Nordisk in partnership with Merrion Pharmaceuticals are developing the GIPET (gastrointestinal 
permeation enhancement technology) system for oral delivery of insulin in the form of a tablet [56]. 
The oral preparation consists of micelles formed with the aid of patented absorption enhancers, which 
have the purpose of increasing absorption across the GI tract. The GIPET formulation in addition to 
having good reproducibility, as stated by the CEO of Merrion Pharmaceuticals, due to the use of GRAS 
ingredients will also result in the development of oral products that are low risk and have good safety 
profiles. The main product is known as GIPET I (OI338GT or NN1953), a long-acting insulin analogue, 
which has managed to reach phase 2 clinical trials. Novo Nordisk are also using the GIPET technology 
to develop oral formulations of two other insulin analogues known as insulin 287 and insulin 320 
(OI320GT or NN1957), which have both completed phase 1 clinical trials [57]. Other than the basic 
information not much can be found about the GIPET formulation or the results of the trials. 
 
Oramed Pharmaceuticals have an oral insulin formulation, known as the ORMD-0801 capsule, which 
is being tested in several phase 2 clinical trials in both type 1 and type 2 diabetic patients [58]. Oramed 
Pharmaceuticals’ Protein Oral DeliveryTM (POD) technology consists of an enteric coated capsule that 
encompasses insulin along with protease inhibitors and absorption enhancers that aid delivery in the 
small intestine. In the phase 2 trial (NCT00867594), eight type 1 diabetic patients, with uncontrolled 
blood glucose levels (HbA1c: 7.5-10%), were trialled with the ORMD-0801 capsules containing 8mg of 
insulin in each capsule [59]. In this trial, the patients were asked to self-administer the ORMD-0801 
capsules three times a day, 45 minutes before their meals, in addition to their standard insulin therapy. 
Although the study included a small number of individuals, and a short treatment period of 10 days, 
the outcome was significantly reduced glycaemia throughout the day. Additionally, the formulation 
was tolerated well by the individuals with no hypoglycaemic episodes or adverse events. One of the 
potential drawbacks to this formulation is the administration of large amount of insulin and it is 
surprising that no hypoglycaemic episodes occurred within the study, but the study was small and the 
effects of interindividual variability will more likely be experienced in larger studies.   
 
Diasome pharmaceuticals have designed an oral HDV (hepatocyte-directed vesicle) insulin gel capsule, 
in which all the insulin is bound to HDV. The HDV vesicle is less than 150 nm in diameter and the 
phospholipid bilayer has specific hepatocyte-targeting molecule (HTM), which in their latest 
preparation is biotin-phosphatidylethanolamine (biotin-PE), incorporated within its structure [60]. As 
reviewed by Geho et al. this formulation not only improves oral insulin delivery by shielding insulin 
from proteolytic enzymes in the upper GI tract, but additionally it is more able to mimic physiological 
insulin delivery via HTM guidance towards hepatocytes. This novel carrier system looks promising and 
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it has been approved by the FDA for initiation of phase 3 clinical trials based on the effectiveness of 
the delivery system in phase 2 human studies. In comparison to other possible oral insulin 
formulations, one of the most promising aspects of this formulation is the amount of insulin contained 
in each capsule, which can be as little as 5 units [43,61]. Accuracy of dosing is highly important with 
insulin treatment and one of the main disadvantages with insulin being given orally is the possibility 
that interindividual variability can lead to overdosing, due to both genetic variations in individuals but 
also factors such as food and transit time in the GI tract, which in theory the risk would be much lower 
with formulations containing smaller amounts of insulin; such as with HDV oral insulin compared to 
formulations with 150 units or more per dose, such as CapsulinTM IR designed by Diabetology [62]. 
 
Oshadi Drug Administrations’ newest formulation is in phase II clinical trials and it has been called 
Oshadi Icp, as it is a combination of insulin, proinsulin and C-peptide. In 2010, the company made a 
patent application for their oral insulin formulation in which it is stated that the preparation comprises 
“a particulate non-covalently associated mixture of pharmacologically inert silica nanoparticles having 
a hydrophobic surface, a branched polysaccharide, and insulin suspended, embedded or dispersed in 
an oil or mixture of oils” [63]. The diameter of the nanoparticles is in the range of 1-100 nanometers. 
Other than the information obtained from the patent (20100278922) there is very little information 
published by the company. The possible reasoning behind the combination of insulin, proinsulin and 
C-peptide in the formulation is to reflect a delivery system similar to endogenous insulin release 
particular as orally delivery insulin reaches the circulation via the hepatic portal vein [64]. 
 
Biocon Limited’s oral insulin tablet IN-105, now known as Tregopil, is a novel insulin analogue [65]. 
Tregopil is a modified form of human insulin where the free amino acid group on the Lys-β29 residue 
has been covalently bonded via a non-hydrolysable amide bond to a small polyethylene glycol (PEG) 
molecule [66]. This modification, in comparison to the original human insulin, has the advantage of 
better stability and reduced degradation in the presence of enzymes in the GIT possibly due to steric 
hindrance. The water solubility of the insulin analogue is also improved and is most likely attributed 
to the presence of the PEG modification. Furthermore, in phase I studies it was found that the amount 
of insulin absorbed was adequately significant to cause reductions in plasma glucose levels, which 
indicated that the alteration aided absorption of the intact insulin peptide in the GIT. After 
administration, based on the initial studies, it was observed that insulin levels peaked at around 20 
minutes and returned to baseline after 1 hour and 20 minutes, which indicates Tregopil could possibly 
be useful for control of postprandial glucose levels [66].  
 
Diabetology (not included in the clinicaltrials.gov search table) is also one of the companies that is 
developing an oral insulin product, known as CapsulinTM IR (insulin replacement), which is in the phase 
2 stage of clinical trials [67]. The insulin (150U or 300U) in the formulation is unmodified and the 
formulation is a simple mixture contained in a standard enteric coated capsule [62]. The oral 
formulation uses the company’s in-licensed AxcessTM drug delivery technology, which contains a 
solubilizer and absorption enhancer but does not include any new chemical entities (NCEs) and has 
demonstrated effectiveness in delivering peptides such as insulin [68]. The main excipients are both 
pharmacopoeial and GRAS listed and include an aromatic alcohol and dissolution aid. The whole 
formulation has been designed to bypass the harsh pH conditions of the stomach and to rapidly 
dissolve in the small intestine (jejunum) allowing all the components to meet the surface of the 
intestinal wall.   
 
Bows Pharmaceutical AG were also developing an oral insulin formulation consisting of insulin in a 
dextran matrix capsule, but it appears that they are no longer active in developing the product with 
the last update being November 2010 [7].  
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As insulin is hydrophilic, the main route of permeation in the GI tract is via the paracellular route [69]. 
Being a protein, the permeability of insulin as well as the oral bioavailability, is likely to be extremely 
low without any absorption enhancement [70]. Therefore, most of the oral insulin formulations being 
developed include absorption enhancers but the likely toxicity of such products is a concern in the 
long term. 
3.4 Nasal insulin delivery 
 
CPEX Pharmaceuticals Inc. has developed an intranasal insulin spray, containing regular short-acting 
human recombinant insulin, given the trade name Nasulin™. The main excipient in the nasal insulin 
formulation is the cyclopentadecalactone (CPE-215), which according to the company has been 
proven to enhance absorption and is known as the permeation enhancement technology of CPEX 
[71,72]. CPE-215 is a naturally occurring compound obtained from the plant Angelica archangelica and 
is contained in many everyday use products including food ingredients, cosmetics and personal 
hygiene. The other components of the formulation include polysorbate 20, sorbitan monolaurate and 
cottonseed oil. During the initial studies in healthy volunteers, it was found that the normal 
physiological nasal cycle did not result in clinically significant alterations in insulin absorption but the 
absorption of insulin was decreased by roughly 50% in those individuals that were affected by total 
nostril blockage [73]. Insulin levels peak at around 10-20 minutes post administration and hence the 
formulation is suitable for prandial glucose control. Nasulin™ is generally well tolerated although 
transient side-effects such as irritation, tickling sensation and sneezing do occur but tend to disappear 
on continued dosing. In the study by Stote et al. 2011 it was concluded that overall the intrasubject 
variability of insulin administered using Nasulin was approximately 40%, which is comparable to that 
of normal subcutaneous administration of insulin.  
3.5 Transdermal insulin delivery 
 
Although in the ClinicalTrials.gov database no transdermal formulations have been reported in the 
past decade, recent searches of reviews show a possible transdermal formulation that is in the later 
stages of clinical trials. It is the non-invasive U-Strip (Ultrasonic Strip) transdermal patch designed by 
Transdermal Specialities, which can be used by both type 1 and type 2 diabetics [74]. This system is a 
two component system, consisting of the insulin patch, which uses an absorbent pad containing up to 
150 units of insulin, that is attached to the second component the U-Strip controller, which is a 
transducer device that generates a unique alternating ultrasonic transmission [75]. The U-Strip system 
utilises two types of ultrasonic waveforms, initially sawtooth waveforms are used to expand the pore 
diameter from roughly 50 µm to 110 µm to facilitate the penetration of large molecules, such as 
insulin, then square waveforms are emitted to actively force insulin through the enlarged pores into 
the dermis and into the blood circulation. The U-Strip device is portable, battery operated, and 
designed to release insulin, specifically insulin lispro, only when the ultrasound is activated. It is also 
programmable, can be worn on either one of the arms or on the belt, and has a touch screen to enable 
patients to control both dosage levels and frequency. Additionally, the device can store data, which is 
transferable via the internet and hence can be a useful record for the management of patient’s 
treatment and compliance by their healthcare team. The information has been provided by Bruce K 
Redding, Jr, who is the president of Transdermal Specialties. Considering that 12 human clinical trials 
have been completed successfully and an additional 500 patient trial is underway the technology looks 
promising and it will be interesting to see further developments in the future.  
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Table 2. Clinical trials submitted appearing on clinicalTrials.gov website involving pulmonary, buccal, 
oral, and nasal insulin delivery systems, for type 1 & 2 diabetes mellitus, with the trial start date being 
between January 2008 and December 2017. No trials recorded for transdermal delivery in the past 
decade [7].   
Pulmonary Insulin Delivery 
Product 
Name  
Company Technology Year Trial 
Started  
Phase NCT Number Reference
(s) 
Dance-
501 
Dance Biopharm Inhaled insulin 
administered using the 
Adagio-01 inhaler 
device (also known as 
dance-501). The device 
uses a vibrating mesh 
micropump technology 
developed by Aerogen. 
2013 1 & 2 NCT02713841 [50] 
2016 1 & 2 NCT02716610 
Afrezza® Mannkind 
Corporation & 
Sanofi 
Technosphere® Insulin 
SAR439065 Afrezza®. 
Technosphere® 
particles are formed 
using the carrier 
fumaryl 
diketopiperazine 
(FDKP). Insulin is 
adsorbed onto the 
particles (around 2 µm 
in size) forming 
Technosphere® insulin. 
2008 1 NCT00673621 [5] 
2 NCT00662857 
1 NCT00674050 
2 NCT00747006 
3 NCT00700622 
2009 3 NCT00642616 
2010 3 NCT01196104 
2011 3 NCT01451398 
3 NCT01445951 
2012 1 NCT01544881 
2015 1 NCT02485327 
1 NCT02470637 
2 NCT02527265 
2017 1 & 2 NCT03234491 
3 NCT03324776 
4 NCT03143816 
4 NCT03313960 
Buccal Insulin Delivery 
Product 
Name  
Company Technology Year Trial 
Started  
Phase NCT Number Reference
(s) 
  
Oral-
lyn™ 
Generex 
Biotechnology 
Corp. 
Formulation contains 
surfactants as 
absorption enhancers 
by forming insulin 
containing micelles. 
Generex Oral-lyn™ 
delivers insulin via a 
2008 3 NCT00668850 [45,47,48] 
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device known as 
RapidMist™. 
Oral Insulin Delivery 
Product 
Name  
Company Technology Year Trial 
Started  
Phase NCT Number Reference
(s) 
GIPET® I Novo Nordisk GIPET® I tablet 
preparation consists of 
micelles formed with 
the aid of patented 
absorption enhancers. 
  
2013 1 NCT01809184 [57] 
2013 1 NCT01796366 
1 NCT01931137 
2014 1 NCT02304627 
2015 2 NCT02470039 
1 NCT02479022 
ORMD-
0801 
Oramed, Ltd. & 
Integrium 
ORMD-0801 consists of 
an enteric coated 
capsule that 
encompasses insulin 
along with protease 
inhibitors and 
absorption enhancers 
that aid delivery in the 
small intestine. 
2008 2 NCT00867594 [59] 
2013 2 NCT01889667 
2014 2 NCT02094534 
2015 2 NCT02535715 
2 NCT02496000 
2016 2 NCT02954601 
Oshadi 
Oral 
Insulin 
Oshadi Drug 
Administration 
Oshadi carrier contains 
a mixture of 
pharmacologically 
inert silica 
nanoparticles with a 
hydrophobic surface 
and a branched 
polysaccharide. Insulin 
is suspended, 
embedded or 
dispersed in an oil or 
mixture of oils 
2010 1 NCT01120912 [64] 
Oshadi Icp (insulin, 
proinsulin and C-
peptide in Oshadi 
carrier) 
2013 1&2 NCT01772251 
2 NCT01973920 
HDV 
Insulin 
Diasome 
Pharmaceuticals 
& Integrium 
In the HDV (hepatocyte 
directed vesicle) insulin 
gel capsule the insulin 
is bound to HDV. The 
HDV vesicle is less than 
2008 2&3 NCT00814294 [61] 
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150 nm in diameter 
and the phospholipid 
bilayer has specific 
hepatocyte-targeting 
molecule (HTM), which 
in the latest 
preparation is biotin-
phosphatidylethanola
mine (biotin-PE). 
2016 2 NCT02794155 
IN-105 Biocon Limited The tablet formulation 
IN-105 oral insulin 
(now known as 
Tregopil) is a modified 
form of human insulin 
where the free amino 
acid group on the Lys-
β29 residue has been 
covalently bonded via a 
non-hydrolysable 
amide bond to a small 
polyethylene glycol 
(PEG) molecule. This 
modification offers 
better stability and 
reduced degradation in 
the presence of 
enzymes in the GIT. 
2010 1 NCT01035801 [66,67] 
ORA2 Bows 
Pharmaceuticals 
AG 
Insulin in dextran 
matrix capsule. 
  
2009 1&2 NCT00990444   
2010 1 NCT01114750 
Nasal Insulin Delivery 
Product 
Name  
Company Technology Year Trial 
Started  
Phase NCT Number Reference
(s) 
Nasulin™ CPEX 
Pharmaceuticals 
Inc. 
The intranasal insulin 
spray contains 
cyclopentadecalactone 
(CPE-215), which is the 
main excipient in the 
permeation 
enhancement 
technology of CPEX. 
2009 2 NCT00850161 [72,73] 
2 NCT00850096 
 
4 Overview of recent therapies 
 
Afrezza® is a newer, non-invasive, rapid-acting inhaled human insulin product, produced by MannKind 
Corporation, that is currently in clinical use in the USA [49]. It was approved, for adults with type 1 
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and type 2 diabetes mellitus, by FDA in June 2014 but in UK and Europe it is currently still in phase 3 
clinical trials [5,76]. The safety and efficacy of Afrezza® was assessed in 3017 patients before the 
formulation was approved by the FDA. The insulin for this portable inhaler product is a dry powder 
formulation, which is contained in single use cartridges comprising of 4, 8 or 12 unit doses of insulin 
[77]. Upon inhalation, which is powered by the patient’s force of inhalation, the Technosphere® insulin 
particles are aerosolized and delivered to the lung alveoli [78]. Technosphere® particles are formed 
using the carrier fumaryl diketopiperazine (FDKP), which under acidic conditions, self-assembles into 
microparticles, and this allows for the recombinant human insulin to adsorb onto the particles (around 
2 µm in size) and form Technosphere® insulin [5,79]. The formed microparticles have median 
diameters of around 2-2.5 micrometers, which enables excellent particle size for delivery of molecules 
to the deep lungs. The alveolar fluid of the deep lungs provides an ideal environment for the rapid 
dissolution of technosphere® insulin; due to the high solubility of the FDPK molecule, in water at 
neutral or basic pH. After absorption across the alveoli into the bloodstream, the FDKP molecule 
remains unchanged and is excreted by the kidneys [78]. Although Afrezza® can be substituted for 
mealtime insulin, patients will still need to inject their long-acting basal insulin [80]. The 
pharmacokinetic and pharmacodynamic properties of Afrezza was assessed in 30 patients with T1DM 
in a recent randomized, controlled 6-way, crossover dose response study [79]. The study looked at the 
comparison of inhaling 4, 12 or 48 units of insulin using Afrezza compared to subcutaneous 
administration of 8, 30 or 90 units of insulin lispro. For inhaled insulin the onset of action was around 
12 minutes, the peak effect occurred between 35-55 minutes and baseline levels were reached around 
90 to 270 minutes. The peak action for insulin lispro, on the other hand, was around 90 to 180 minutes 
with baseline levels reaching between 360 to 660 minutes. Nonetheless, the baseline levels for both 
Afrezza and insulin lispro were noted to have reached in a dose-dependent manner. Based on the data 
in this study for insulin lispro, as well as the results for Humalog® published on the electronic 
medicines compendium and shown in Table 3, it can be seen that in comparison to subcutaneous 
administration the inhaled Afrezza is both faster in onset and has a shorter duration of action [81]. As 
shown in Figure 3, there are many advantages for delivering insulin via the pulmonary route but there 
are also quite a few disadvantages and some of these are experienced with Afrezza® as it is not suitable 
for patients with chronic lung disease, due to risk of acute bronchospasm, and not recommended for 
smokers or those who have recently quit smoking [49].  
 
Table 3. Comparison of the pharmacokinetic and pharmacodynamic profile of a current 
subcutaneous rapid acting insulin and the newer buccal and inhaled insulin formulations. 
Product Type of 
insulin 
Route/method 
of 
administration 
Onset of 
action 
(minutes) 
Peak 
action 
(minutes) 
Time for 
effect to 
return to 
baseline 
(minutes) 
Reference(s) 
Humalog® Rapid acting 
insulin lispro 
Injected in the 
subcutaneous 
tissue 
~ 15 ~ 90 ~ 120 to 
300 
[81] 
Oral-lyn™ Regular 
human insulin 
Sprayed on the 
buccal 
membrane 
~ 32 ~ 44 ~ 85 [86] 
Afrezza® Recombinant 
human insulin 
Inhaled for 
absorption in the 
deep lungs 
~ 12 ~ 35 to 55 ~ 90 to 
270 
[79] 
 
Another product of interest is the Generex Oral-lyn™ (or Oralin™) spray, produced by the Canadian 
company Generex Biotechnology, for use as prandial insulin in T1DM and T2DM. It has been approved 
for clinical use in Ecuador and Lebanon but in Canada, US and Europe the product is still in phase 3 
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clinical trials [6,43,82]. Oral-lyn™ has been approved by the FDA for treatment of patients under the 
Investigational New Drug (IND) program, which allows the drug to be accessible to patients with 
serious or life-threatening Type 1 or Type 2 diabetes mellitus who are not eligible for the phase 3 
clinical trials and there are no other alternative satisfactory treatment [82]. The insulin within the 
preparation is stable at room temperature for at least six months and is formulated using a 
combination of absorption enhancers and small amounts of excipients classified by the FDA as 
generally recognised as safe (GRAS) [43,83]. In the formulation surfactants, which form insulin 
containing micelles, are used as absorption enhancers and this appears to be a critical component of 
the Generex drug delivery system. Generex Oral-lyn™ delivers insulin via a device known as 
RapidMist™, which in appearance is similar to metered dose systems used in asthma and chronic 
obstructive pulmonary disease treatment [84]. It delivers regular human insulin to the buccal mucosa; 
the insulin containing micelles are larger than 7µm and hence are too big to reach alveoli and are 
impacted in the buccal cavity. Each canister contains 400 units of insulin and while 1 puff holds 10 
units of insulin only 10% of the drug is absorbed; hence with each spray 1 unit of insulin is delivered 
to the blood circulation [43,84]. In practice many patients require 10 units or more of insulin with each 
meal, some considerably more, and hence using the device to administer 10 or more puffs each time 
can be become inconvenient and may not be feasible for the long-term. In a comparative study of 
insulin levels in type 1 diabetic patients, where Oral-lyn™ insulin was compared to sc injections of 
insulin or placebo, it was observed that with Oral-lyn™ the entry of insulin into the blood circulation 
was much faster compared to sc injections and insulin levels could be detected within 10 minutes of 
administration [85]. Additionally, Oral-lyn™ insulin reached peak insulin levels at 30 minutes whereas 
sc injections were much slower in comparison. At 150 minutes Oral-lyn™ insulin had almost reached 
baseline level whereas sc injections of insulin were still around peak levels. This small study, together 
with another study (data shown in Table 3), demonstrates that  buccal insulin could possibly be more 
reflective of normal insulin response to meal intake in non-diabetic individuals compared to sc 
injection, taking less time to reach peak activity and having a shorter duration of action [85,86]. 
Although there are some advantages of the Oral-lyn™ device and formulation, the low bioavailability 
of the formulation can be a major drawback for the product obtaining approval worldwide.  
5 Conclusion and future directions 
 
Insulin forms a major part in the diabetes treatment plan. In the future the ideal and most convenient 
situation for diabetic patients would be to take insulin orally in the form of a tablet or capsule but 
based on the challenges of delivering proteins via the GI tract, the success of such a concept needs 
further development. On a positive note, even though many have failed, most trials in relation to 
insulin are related to oral delivery products. Hence there is some possibility that an orally delivered 
insulin formulation will be approved by regulatory authorities (e.g. MHRA and FDA) in the next decade 
or two. The challenge is finding a formulation that is clinically effective, safe and convenient for long-
term daily administration. But if this is achieved, it will likely be for a long-acting basal insulin 
formulation, in order to minimise use of excipients, such as absorption enhancers or enzyme 
inhibitors, and also to overcome challenges, such as the fed and fasted state, and to avoid the critical 
timing associated with lowering meal time glucose levels in the systemic circulation. One of the main 
products that appear promising is the oral HDV insulin gel capsule; as this formulation allows for a low 
dose of insulin to be used and as such it has the theoretical benefit of having a lower risk of 
hypoglycaemia compared to the other oral preparations that contain much higher doses of insulin. 
 
Two other promising non-invasive products include the Dance-501 hand-held insulin inhaler device 
and the U-strip transdermal insulin patch system. The Dance-501 device has overcome many of the 
weaknesses faced by the Exubera and has several advantages in terms of the design: as it is small, 
discrete and more patient friendly for use outside the home. But this new inhaled insulin delivery 
system has the drawback of requiring administration of 10 times more insulin in order to obtain the 
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equivalent amount of insulin from subcutaneous administration of insulin. If the bioavailability can be 
improved the Dance-501 device can have a promising future ahead. The U-Strip system is another 
innovative technology. It is unique as the transdermal delivery of insulin is enhanced by combining 
two types of ultrasonic waveforms. Although currently a relatively bulky controller is required, it 
would be advantageous if this can be reduced in size, but overall the technology appears promising 
and the outcome of the current clinical trials will be of interest once revealed. Afrezza® has been FDA 
approved; nonetheless still faces a number of challenges including obtaining approval in Europe. 
Generex Oral-lyn™ spray also requires approval in Europe, the USA and many other countries 
worldwide. Once these two products become approved and in common use in Europe and the USA 
then will non-invasive insulin administration become a reality and allow for other newer formulations 
to have a better opportunity of success and approval. There are many challenges to overcome but 
achievement of a formulation, that can replace subcutaneous injections, would not only be a great 
accomplishment scientifically, in terms of delivering a protein safely for chronic use non-invasively, 
but also a major contribution to easing the lives of millions of patients and reducing healthcare costs 
worldwide.  
 
6 References 
 
[1] World Health Organization. Global report on diabetes. France: 2016. 
[2] Wild S, Roglic G, Green A, Sicree R, King H. Global Prevalence of Diabetes. Diabetes Care 
2004;27:1047–53. 
[3] Whiting DR, Guariguata L, Weil C, Shaw J. IDF Diabetes Atlas: Global estimates of the 
prevalence of diabetes for 2011 and 2030. Diabetes Res Clin Pract 2011;94:311–21. 
doi:10.1016/J.DIABRES.2011.10.029. 
[4] Cho NH, Shaw JE, Karuranga S, Huang Y, da Rocha Fernandes JD, Ohlrogge AW, et al. IDF 
Diabetes Atlas: Global estimates of diabetes prevalence for 2017 and projections for 2045. 
Diabetes Res Clin Pract 2018;138:271–81. doi:10.1016/j.diabres.2018.02.023. 
[5] Klonoff DC. Afrezza Inhaled Insulin. J Diabetes Sci Technol 2014;8:1071–3. 
[6] Morales JO, Brayden JD. Buccal delivery of small molecules and biologics: of mucoadhesive 
polymers, films, and nanoparticles. Curr Opin Pharmacol 2017;36:22–8. 
[7] U.S. National Library of Medicine. Insulin Interventional Studies Diabetes 2017. 
https://clinicaltrials.gov/ (accessed December 23, 2017). 
[8] Ashcroft F, Ashcroft S. Insulin synthesis. Insul. Mol. Biol. to Pathol., USA: Oxford University 
Press; 1992, p. 64–87. 
[9] World Health Organization. Definition, Diagnosis and Classification of Diabetes Mellitus and 
its Complications. Geneva: 1999. 
[10] The Diabetes Control and Complications Trial Research Group. The effect of intensive 
treatment of diabetes on the development and progression of long-term complications in 
insulin-dependent diabetes mellitus. N Engl J Med 1993;329:977–86. 
[11] Research CT, The Diabetes Control and Complications Trial Research Group. Effect of 
intensive diabetes treatment on the development and progression of long-term 
complications in adolescents with insulin-dependent diabetes mellitus: Diabetes Control and 
Complications Trial. J Pediatr 1994;125:177–88. 
19 
 
[12] Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and 
Complications Research Group, Lachin JM, Genuth S, Cleary P, Davis MD, Nathan DM. 
Retinopathy and nephropathy in patients with type 1 diabetes four years after a trial of 
intensive therapy. N Engl J Med 2000;342:381–9. 
[13] Banting FB, Best CH. The internal secretion of the pancreas. J Lab Clin Med 1922;7:251–66. 
[14] Madison JH. Manufacturing Pharmaceuticals: Eli Lilly and Company, 1876-1948. Bus Econ Hist 
1989;18:72–8. 
[15] Gatchair SD, Bortagaray I, Brito L, Brouwer R. Uneven publics:life, death, and recombinant 
insulin. Innov. Inequal.  Emerg. Technol. an unequal world, Cheltenham, Northampton: 
Edward Elgar Publishing; 2014, p. 67–76. 
[16] Howey DC, Bowsher RR, Brunelle RL, Woodworth JR. Lys(B28), Pro(B29)]-human insulin. A 
rapidly absorbed analogue of human insulin. Diabetes 1994;43:396–402. 
[17] Crommelin DJA. Insulin. In: Sindelar RD, Meibohm B, editors. Pharm. Biotechnol. Fundam. 
Appl. 3rd ed., Hoboken: Taylor and Francis; 2007, p. 265–78. 
[18] Heinemann L. The failure of exubera: are we beating a dead horse? J Diabetes Sci Technol 
2008;2:518–29. 
[19] FDA. FDA News Release: FDA approves two new drug treatments for diabetes mellitus 2015. 
https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm464321.htm 
(accessed February 20, 2017). 
[20] European Medicines Agency. EMEA-000456-PIP01-08-M02 2014. 
http://www.ema.europa.eu/ema//index.jsp?curl=pages/medicines/pips/EMEA-000456-
PIP01-08-M02/pip_000397.jsp (accessed March 20, 2017). 
[21] European Medicines Agency. Find medicine: Fiasp insulin aspart 2017. 
http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/004046
/human_med_002063.jsp (accessed March 20, 2017). 
[22] Heise T, Hövelmann U, Brøndsted L, Adrian CL, Nosek L, Haahr H. Faster-acting insulin aspart: 
earlier onset of appearance and greater early pharmacokinetic and pharmacodynamic effects 
than insulin aspart. Diabetes, Obes Metab 2015;17:682–8. 
[23] Fu Z, Gilbert ER, Liu D. Regulation of insulin synthesis and secretion and pancreatic Beta-cell 
dysfunction in diabetes. Curr Diabetes Rev 2013;9:25–53. 
[24] Matteucci E, Giampietro O, Covolan V, Giustarini D, Fanti P, Rossi R. Insulin administration: 
present strategies and future directions for a noninvasive (possibly more physiological) 
delivery. Drug Des Devel Ther 2015;9:3109–18. 
[25] Guo H, Xiong Y, Witkowski P, Cui J, Wang LJ, Sun J, et al. Inefficient translocation of 
preproinsulin contributes to pancreatic beta cell failure and late-onset diabetes. J Biol Chem 
2014;289:16290–302. 
[26] Poitout V, Hagman D, Stein R, Artner I, Robertson RP, Harmon JS. Regulation of the insulin 
gene by glucose and fatty acids. J Nutr 2006;136:873–6. 
[27] Wolin SL, Walter P. Discrete nascent chain lengths are required for the insertion of 
presecretory proteins into microsomal membranes. J Cell Biol 1993;121:1211–9. 
[28] Okun MM, Shields D. Translocation of preproinsulin across the endoplasmic reticulum 
membrane. The relationship between nascent polypeptide size and extent of signal 
20 
 
recognition particle-mediated inhibition of protein synthesis. J Biol Chem 1992;267:11476–
82. 
[29] Patzelt C, Labrecque AD, Duguid JR, Carroll RJ, Keim PS, Heinrikson RL, et al. Detection and 
kinetic behavior of preproinsulin in pancreatic islets. Proc Natl Acad Sci U S A 1978;75:1260–
4. 
[30] Chan SJ, Keim P, Steiner DF. Cell-free synthesis of rat preproinsulins: characterization and 
partial amino acid sequence determination. Proc Natl Acad Sci U S A 1976;73:1964–8. 
[31] Beckers CJ, Balch WE. Calcium and GTP: essential components in vesicular trafficking 
between the endoplasmic reticulum and Golgi apparatus. J Cell Biol 1989;108:1245–56. 
[32] Dunn MF. Zinc–ligand interactions modulate assembly and stability of the insulin hexamer–a 
review. Biometals 2005;18:295–303. 
[33] Galloway JA, Chance RE. Improving insulin therapy: achievements and challenges. Horm 
Metab Res 1994;26:591–8. 
[34] Hyllested-Winge J, Jensen KH, Rex J. A Review of 25 Years’ Experience with the NovoPen® 
Family of Insulin Pens in the Management of Diabetes Mellitus. Clin Drug Investig 
2010;30:643–74. 
[35] Joint Formulary Committee. Chapter 6: Endocrine System. Br. Natl. Formul. 72, London: BMJ 
Group & Pharmaceutical Press; 2016, p. 640–6. 
[36] Anhalt H, Bohannon NJ V. Insulin patch pumps: their development and future in closed-loop 
systems. Diabetes Technol Ther 2010;12:51–8. 
[37] Zisser HC. The OmniPod Insulin Management System: the latest innovation in insulin pump 
therapy. Diabetes Ther 2010;1:10–24. 
[38] Winter A, Lintner M, Knezevich E. V-Go Insulin Delivery System Versus Multiple Daily Insulin 
Injections for Patients With Uncontrolled Type 2 Diabetes Mellitus. J Diabetes Sci Technol 
2015;9:1111–6. 
[39] Gilbert M, Pratley RE. V-GoTM—A Novel Device for Delivering Basal–Bolus Insulin Therapy to 
Patients with Type 2 Diabetes Mellitus. 2007. 
[40] Harris D, Robinson JR. Drug Delivery via the Mucous Membranes of the Oral Cavity. J Pharm 
Sci 1992;81:1–10. 
[41] Shojaei AH. Buccal mucosa as a route for systemic drug delivery: a review. J Pharm Sci 
1998;1:15–30. 
[42] Tanner T, Marks R. Delivering drugs by the transdermal route: review and comment. Ski Res 
Technol 2008;14:249–60. 
[43] Heinemann L, Jacques Y. Oral insulin and buccal insulin: a critical reappraisal. J Diabetes Sci 
Technol 2009;3:568–84. 
[44] Henkin RI. Inhaled insulin—Intrapulmonary, intranasal, and other routes of administration: 
Mechanisms of action. Nutrition 2010;26:33–9. 
[45] Hultstrom M, Roxhed N, Nordquist L. Intradermal insulin delivery: a promising future for 
diabetes management. J Diabetes Sci Technol 2014;8:453–7. 
[46] Cavaiola TS, Edelman S. Inhaled insulin: a breath of fresh air? A review of inhaled insulin. Clin 
Ther 2014;36:1275–89. 
21 
 
[47] Silva BMA, Borges AF, Silva C, Coelho JFJ, Simões S. Mucoadhesive oral films: The potential for 
unmet needs. Int J Pharm 2015;494:537–51. 
[48] Rathbone MJ, Pather I, Şenel S. Overview of Oral Mucosal Delivery. Oral Mucosal Drug Deliv. 
Ther., Boston: Springer; 2015, p. 17–29. 
[49] FDA. AFREZZA® (insulin human) Inhalation Powder 2014. 
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/022472Orig1s000TOC.cfm 
(accessed January 21, 2018). 
[50] Fink JB, Molloy L, Patton JS, Galindo-Filho VC, de Melo Barcelar J, Alcoforado L, et al. Good 
Things in Small Packages: an Innovative Delivery Approach for Inhaled Insulin. Pharm Res 
2017;34:2568–78. 
[51] Kim D, Mudaliar S, Chinnapongse S, Chu N, Boies SM, Davis T, et al. Dose-response 
relationships of inhaled insulin delivered via the Aerodose insulin inhaler and subcutaneously 
injected insulin in patients with type 2 diabetes. Diabetes Care 2003;26:2842–7. 
[52] Midatech Pharma. News Release: Initiation of Phase IIa study of insulin delivery via buccal 
strip for type 1 diabetes 2015. http://www.midatechpharma.com/news/49/143/Initiation-of-
Phase-IIa-study-of-insulin-delivery-via-buccal-strip-for-type-1-diabetes.html (accessed March 
20, 2017). 
[53] Morales JO, Fathe KR, Brunaugh A, Ferrati S, Li S, Montenegro-Nicolini M, et al. Challenges 
and Future Prospects for the Delivery of Biologics: Oral Mucosal, Pulmonary, and Transdermal 
Routes. AAPS J 2017;19:652–68. 
[54] Midatech Pharma. Midatech’s primary platform technology is based on carbohydrate-coated 
gold nanoparticle (GNP) drug conjugates. 2017. http://www.midatechpharma.com/gnp-
technology (accessed March 20, 2017). 
[55] Midatech Pharma. News Release: Midatech Pharma announces clinical pipeline update 2016. 
http://www.midatechpharma.com/news/69/143/Midatech-Pharma-announces-clinical-
pipeline-update.html (accessed March 21, 2017). 
[56] Fonte P, Araujo F, Reis S, Sarmento B. Oral insulin delivery: how far are we? J Diabetes Sci 
Technol 2013;7:520–31. 
[57] Novo Nordisk. Company announcement: Financial report for the period 1 January 2015 to 30 
June 2015. 2015. 
[58] Oramed Pharmaceuticals. Technology 2016. http://www.oramed.com/technology/ (accessed 
February 5, 2017). 
[59] Eldor R, Arbit E, Corcos A, Kidron M. Glucose-Reducing Effect of the ORMD-0801 Oral Insulin 
Preparation in Patients with Uncontrolled Type 1 Diabetes: A Pilot Study. PLoS One 
2013;8:e59524. 
[60] Geho WB, Geho HC, Lau JR, Gana TJ. Hepatic-directed vesicle insulin: a review of formulation 
development and preclinical evaluation. J Diabetes Sci Technol 2009;3:1451–9. 
[61] Diasome Pharmaceuticals. Pipeline 2016. http://diasomepharmaceuticals.com/pipeline/ 
(accessed February 11, 2017). 
[62] Luzio SD, Dunseath G, Lockett A, Broke-Smith TP, New RR, Owens DR. The glucose lowering 
effect of an oral insulin (Capsulin) during an isoglycaemic clamp study in persons with type 2 
diabetes. Diabetes, Obes Metab 2010;12:82–7. 
22 
 
[63] Gribova O, Vol A. Methods and compositions for oral administration of insulin. 20100278922, 
2010. 
[64] Zijlstra E, Heinemann L, Plum-Mörschel L. Oral Insulin Reloaded: A Structured Approach. J 
Diabetes Sci Technol 2014;8:458–65. 
[65] Biocon. Active Discovery Programs 2016. 
http://www.biocon.com/biocon_research_discovery.asp (accessed February 19, 2017). 
[66] Khedkar A, Iyer H, Anand A, Verma M, Krishnamurthy S, Savale S, et al. A dose range finding 
study of novel oral insulin (IN-105) under fed conditions in type 2 diabetes mellitus subjects. 
Diabetes, Obes Metab 2010;12:659–64. 
[67] Diabetology. Capsulin 2017. http://www.diabetology.co.uk/projects/capsulin/ (accessed 
March 31, 2018). 
[68] Diabetology. Axcess Oral Delivery System 2017. http://www.diabetology.co.uk/technology/ 
(accessed March 31, 2018). 
[69] Muheem A, Shakeel F, Jahangir MA, Anwar M, Mallick N, Jain GK, et al. A review on the 
strategies for oral delivery of proteins and peptides and their clinical perspectives. Saudi 
Pharm J 2016;24:413–28. 
[70] Swenson SE, Curatolo WJ. (C) Means to enhance penetration: (2) Intestinal permeability 
enhancement for proteins, peptides and other polar drugs: mechanisms and potential 
toxicity. Adv Drug Deliv Rev 1992;8:39–92. 
[71] CPEX Pharmaceuticals. Permeation Enhancement Technology 2011. 
http://www.cpexpharmaceuticals.com/permeation-technology.html (accessed February 19, 
2017). 
[72] Stote R, Miller M, Marbury T, Shi L, Strange P. Enhanced absorption of NasulinTM, an 
ultrarapid-acting intranasal insulin formulation, using single nostril administration in normal 
subjects. J Diabetes Sci Technol 2011;5:113–9. 
[73] Leary AC, Dowling M, Cussen K, O’Brien J, Stote RM. Pharmacokinetics and 
pharmacodynamics of intranasal insulin spray (NasulinTM) administered to healthy male 
volunteers: influence of the nasal cycle. J Diabetes Sci Technol 2008;2:1054–60. 
[74] Shahani S, Shahani L. Use of insulin in diabetes: a century of treatment. Hong Kong Med J = 
Xianggang Yi Xue Za Zhi 2015;21:553–9. 
[75] Redding BK. Transdermal Specialties: Designing an ultrasound enabled patch for Insulin. 
Frederick Furness Publ Ltd 2014:22–6. 
[76] Specialist Pharmacy Service. Insulin Inhaled 2017. https://www.sps.nhs.uk/medicines/insulin-
inhaled/ (accessed October 15, 2018). 
[77] Goldberg T, Wong E. Afrezza (Insulin Human) Inhalation Powder: A New Inhaled Insulin for 
the Management Of Type-1 or Type-2 Diabetes Mellitus. P T 2015;40:735–41. 
[78] Kim ES, Plosker GL. AFREZZA® (insulin human) Inhalation Powder: A Review in Diabetes 
Mellitus. Drugs 2015;75:1679–86. 
[79] Heinemann L, Parkin CG. Rethinking the Viability and Utility of Inhaled Insulin in Clinical 
Practice. J Diabetes Res 2018;2018:1–9. doi:10.1155/2018/4568903. 
[80] Fleming LW, Fleming JW, Davis CS. Afrezza: An inhaled approach to insulin delivery. J Am 
23 
 
Assoc Nurse Pract 2015;27:597–601. 
[81] Eli Lilly and Company Limited. Humalog 100 units/ml KwikPen, solution for injection in a pre-
filled pen 2018. https://www.medicines.org.uk/emc/product/8545/smpc (accessed October 
16, 2018). 
[82] Specialist Pharmacy Service. Insulin Buccal 2018. https://www.sps.nhs.uk/medicines/insulin-
buccal/ (accessed October 15, 2018). 
[83] Park K, Kwon IC, Park K. Oral protein delivery: Current status and future prospect. React Funct 
Polym 2011;71:280–7. 
[84] Bernstein G. Delivery of insulin to the buccal mucosa utilizing the RapidMistTM system. Expert 
Opin Drug Deliv 2008;5:1047–55. 
[85] Modi P, Mihic M, Lewin A. The evolving role of oral insulin in the treatment of diabetes using 
a novel RapidMistTM system. Diabetes Metab Res Rev 2002;18:38–42. 
[86] Pozzilli P, Raskin P, Parkin CG. Review of clinical trials: update on oral insulin spray 
formulation. Diabetes, Obes Metab 2009;12:91–6. doi:10.1111/j.1463-1326.2009.01127.x. 
 
